With its back against the wall, Regulus hands over its lead microRNA drug to Sanofi for a small down payment
Just a few weeks after a troubled Regulus Therapeutics $RGLS pulled off a reverse split of its stock, the biotech is handing off its lead …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
